Targeting ACE2 for COVID-19 Therapy: Opportunities and Challenges
| Autor: | Hongpeng Jia, Honggang Cui, Enid Neptune |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Clinical Biochemistry ACE2 Disease 03 medical and health sciences Drug Delivery Systems 0302 clinical medicine Viral entry Pandemic Humans Medicine Molecular Biology License therapy Innate immune system SARS-CoV-2 business.industry COVID-19 Cell Biology Creative commons Immunity Innate COVID-19 Drug Treatment 030104 developmental biology 030228 respiratory system Risk analysis (engineering) Spike Glycoprotein Coronavirus Angiotensin-Converting Enzyme 2 business Perspectives |
| Zdroj: | American Journal of Respiratory Cell and Molecular Biology |
| ISSN: | 1535-4989 1044-1549 |
| Popis: | COVID-19 pandemic is sweeping the globe, even with the effective vaccine is on the horizon, new cases, and escalating mortality climbing every day. Angiotensin-converting enzyme 2 (ACE2) is the primary receptor for COVID-19 causative virus, SARS-CoV-2, and its complexation with spike proteins plays a crucial role in viral entry into host cells and the subsequent infection. Blocking this binding event, or reducing the accessibility of the virus to the ACE2 receptor, represents an alternative strategy to prevent COVID-19 disease. In addition, the biological significance of ACE2 in modulating the innate immune system and tissue repair cascades anchors its therapeutic potential for treating the infected patients. In this viewpoint article, we review the current efforts of exploiting ACE2 as a therapeutic target to address this dire medical need. We also provide a holistic view of the pros and cons of each treatment strategy. We highlight the fundamental and translational challenges in moving these research endeavors to clinical applications. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|